| Company/Division name | Kemwell Biopharma |
| Parent company | Recipharm |
| Type of work | Manufacturing |
| If manufacturing, is the company a contract manufacturer? | Yes |
| Reshoring category: | Foreign Direct Investment |
| Year reshoring announced: | 2021 |
| Year reshoring implemented or to be implemented: | 2021 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 25 |
| Country(ies) from which reshored: | India |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | biopharma, pharmaceuticals |
| What domestic positive factors made reshoring more attractive? | Under-utilized capacity |
